Mostafa Ronaghi,
Senior Vice President And Chief Technology Officer,
Illumina Inc
Mostafa Ronaghi, Ph.D., joined Illumina in August 2008. As Senior Vice President and Chief Technology Officer, he is responsible for leading internal research and the Illumina accelerator program. Dr. Ronaghi is an experienced entrepreneur and was involved in the start-up of four life sciences companies. In 2007, Ronaghi co-founded Avantome, a privately held sequencing company (acquired by Illumina in 2008). Before this, he co-founded NextBio, a search engine for life science data (acquired by Illumina in 2013). In 2001, Ronaghi co-founded ParAllele Bioscience, which was eventually acquired by Affymetrix, Inc., and was involved in the development and commercialization of highly multiplexed technology for genetic testing. In 1997, he co-founded Pyrosequencing AB, which was renamed to Biotage in 2003, and led the company to a successful initial public offering in June 2000 on the Stockholm Stock Exchange. Dr. Ronaghi was a principal investigator at Stanford University from 2002 until 2008 and focused on the development of novel tools for molecular diagnostic applications. He serves on the board of directors of Clear Labs and BaseHealth. Dr. Ronaghi earned his Ph.D. from the Royal Institute of Technology in Sweden. He holds more than 30 (pending and issued) patents and has written more than 70 peer-reviewed publications in journals and books.
Precision Medicine Empowered by Genomics
Wednesday, 30 September 2015 at 11:00
Add to Calendar ▼2015-09-30 11:00:002015-09-30 12:00:00Europe/LondonPrecision Medicine Empowered by GenomicsNGS, SCA, Mass Spec: The Road to Diagnostics in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Recent advancements in genomic technologies are changing the scientific horizon, dramatically accelerating biomedical research. For wide implementation of these technologies, their accuracy, throughput, cost, and workflow need to be addressed. In the past ten years, the cost of full human genome sequencing has been reduced by 4-5 orders of magnitude, and reduction will continue by another 10-fold in the next few years. In this talk we will discuss the recent progress of Illumina in introducing new genomics tools and their implementation in precision medicine initiative.
Add to Calendar ▼2015-09-28 00:00:002015-09-30 00:00:00Europe/LondonNGS, SCA, Mass Spec: The Road to DiagnosticsNGS, SCA, Mass Spec: The Road to Diagnostics in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com